According to DelveInsight’s latest automated suturing devices research report – forecast till 2030, the sector is entering a phase of measured but consistent expansion, underpinned by evolving surgical practice, demographic pressure, and a steady stream of regulatory milestones. Valued at USD 2.53 billion in 2023, the industry is forecast to advance at a CAGR of 6.81% through 2030, culminating in a projected valuation of USD 3.74 billion.
At its core, an automated suturing device addresses a persistent operating-room challenge: the time, skill, and consistency required for manual wound closure. By mechanizing the suturing process, these systems help standardize outcomes across cardiovascular, gynecological, gastrointestinal, and orthopedic procedures, positioning the broader automated suturing devices market as a meaningful contributor to modern surgical efficiency.
Forces Behind the Momentum
Global cancer incidence remains a central pressure point. WHO figures from 2022 place breast cancer at the top of the list with 2.26 million new diagnoses in 2020, trailed by lung, colorectal, and prostate cancers. Each diagnosis carries downstream implications for surgical scheduling, and by extension, for demand tied to the automatic suture device category.
Injury data tells a parallel story. The WHO estimates that 20 to 50 million people worldwide sustain non-fatal injuries each year, a meaningful share of which result in lasting disability. The International Labour Organization adds that roughly 340 million occupational accidents occur annually. Together, these figures translate into a steady baseline of surgical demand that supports device manufacturers well beyond elective procedure volumes alone.
Regulatory activity has also kept pace. Endo Tools Therapeutics secured FDA clearance for its Endomina system in January 2022, enabling endoscopic suture placement within the gastrointestinal tract. Six months earlier, Anchora Medical’s Su2ura Approximation Device received 510(k) clearance for laparoscopic soft-tissue closure. Developments like these are gradually reshaping the endoluminal suturing devices market, extending automated closure technology into procedures once reserved for manual technique.
Headwinds Worth Watching
Growth is not without friction. A shortage of clinicians trained on newer platforms, uneven device availability across regions, and the premium pricing of automated systems relative to conventional sutures continue to temper adoption in certain markets. The pandemic-era slowdown in elective surgery also left a temporary dent in demand, though procedure volumes have largely normalized since.
Where Demand Concentrates
Gynecological applications stand out as a particularly active segment. WHO data cites roughly 604,000 new cervical cancer cases globally in 2020, while ovarian and endometrial cancers separately account for hundreds of thousands more diagnoses each year. This procedural volume feeds directly into the gynecology suture market, reinforcing it as one of the stronger application-based growth pockets through 2030.
Regionally, North America is expected to retain its lead. More than 13 million surgical procedures were performed across the United States between January 2019 and January 2021 per WHO figures, while nearly 55.4 million motor-vehicle-related injuries were recorded in 2020 alone. CDC estimates that six in ten American adults manage at least one chronic condition, a trend that continues to feed procedure volumes across the us automated suturing devices market and, by extension, the adjacent us wound closure devices market.
Companies shaping this landscape include Medtronic, LSI Solutions, Sutrue Limited, Apollo Endosurgery, B. Braun Melsungen AG, Becton, Dickinson & Company, Ethicon (Johnson & Johnson), Smith & Nephew, EndoEvolution, Mellon Medical B.V., Endo Tools Therapeutics, EDGe Surgical, Medical Microinstruments, and SuturTek, among others.
Looking Ahead
As regulatory pathways mature and procedural demand broadens across specialties, the outlook for this industry through 2030 remains constructive. For readers tracking adjacent opportunities, DelveInsight’s coverage extends further into the suture anchor device market, the cardiac sutures market, and the united states surgical sutures market, each offering a closer look at the surrounding wound closure ecosystem.
Latest Reports Offered by Delveinsight
guillain-barré syndrome market | hay fever conjunctivitis market | hidradenitis suppurativa market | house dust mite allergy market | hpv-induced cutaneous tumors market | hyperglycemia market | hypothyroidism market | hypoxia market | indwelling catheters market | intraocular lymphoma market | iron deficiency anemia market | laron syndrome market | mrna based vaccines and therapeutics market | myocarditis market | partial onset seizures market | penile cancer market | sacral nerve stimulator market | spinal cord injury market | surgical site infections market | transcatheter embolization and occlusion devices r | vaso-occlusive crisis market | wilson’s disease market | acquired immunodeficiency syndrome market | acute gout flare market | acute pancreatitis market | acute respiratory distress syndrome market | adrenal insufficiency market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk